151 related articles for article (PubMed ID: 37210178)
21. The Current Lung Cancer Neoantigen Landscape and Implications for Therapy.
Ye L; Creaney J; Redwood A; Robinson B
J Thorac Oncol; 2021 Jun; 16(6):922-932. PubMed ID: 33581342
[TBL] [Abstract][Full Text] [Related]
22. Evolution of Radiological Treatment Response Assessments for Cancer Immunotherapy: From iRECIST to Radiomics and Artificial Intelligence.
Kim N; Lee ES; Won SE; Yang M; Lee AJ; Shin Y; Ko Y; Pyo J; Park HJ; Kim KW
Korean J Radiol; 2022 Nov; 23(11):1089-1101. PubMed ID: 36098343
[TBL] [Abstract][Full Text] [Related]
23. [18F]FDG PET immunotherapy radiomics signature (iRADIOMICS) predicts response of non-small-cell lung cancer patients treated with pembrolizumab.
Valentinuzzi D; Vrankar M; Boc N; Ahac V; Zupancic Z; Unk M; Skalic K; Zagar I; Studen A; Simoncic U; Eickhoff J; Jeraj R
Radiol Oncol; 2020 Jul; 54(3):285-294. PubMed ID: 32726293
[TBL] [Abstract][Full Text] [Related]
24. The biology and management of non-small cell lung cancer.
Herbst RS; Morgensztern D; Boshoff C
Nature; 2018 Jan; 553(7689):446-454. PubMed ID: 29364287
[TBL] [Abstract][Full Text] [Related]
25. The effects of radiotherapy on the survival of patients with unresectable non-small cell lung cancer.
Tini P; Nardone V; Pastina P; Pirtoli L; Correale P; Giordano A
Expert Rev Anticancer Ther; 2018 Jun; 18(6):593-602. PubMed ID: 29582686
[TBL] [Abstract][Full Text] [Related]
26. Targeted Therapy and Immunotherapy in the Treatment of Non-Small Cell Lung Cancer.
Shroff GS; de Groot PM; Papadimitrakopoulou VA; Truong MT; Carter BW
Radiol Clin North Am; 2018 May; 56(3):485-495. PubMed ID: 29622080
[TBL] [Abstract][Full Text] [Related]
27. Noninvasive imaging in cancer immunotherapy: The way to precision medicine.
Du Y; Qi Y; Jin Z; Tian J
Cancer Lett; 2019 Dec; 466():13-22. PubMed ID: 31499119
[TBL] [Abstract][Full Text] [Related]
28. Tumor Mutation Burden: Leading Immunotherapy to the Era of Precision Medicine?
Steuer CE; Ramalingam SS
J Clin Oncol; 2018 Mar; 36(7):631-632. PubMed ID: 29337637
[No Abstract] [Full Text] [Related]
29. Incorporating Immunotherapy Into the Treatment of Non-Small Cell Lung Cancer: Practical Guidance for the Clinic.
Socinski MA
Semin Oncol; 2015 Oct; 42 Suppl 2():S19-28. PubMed ID: 26477471
[TBL] [Abstract][Full Text] [Related]
30. Circulating biomarkers predictive of tumor response to cancer immunotherapy.
Lee EY; Kulkarni RP
Expert Rev Mol Diagn; 2019 Oct; 19(10):895-904. PubMed ID: 31469965
[No Abstract] [Full Text] [Related]
31. An Immunogram for the Cancer-Immunity Cycle: Towards Personalized Immunotherapy of Lung Cancer.
Karasaki T; Nagayama K; Kuwano H; Nitadori JI; Sato M; Anraku M; Hosoi A; Matsushita H; Morishita Y; Kashiwabara K; Takazawa M; Ohara O; Kakimi K; Nakajima J
J Thorac Oncol; 2017 May; 12(5):791-803. PubMed ID: 28088513
[TBL] [Abstract][Full Text] [Related]
32. The Emerging Role of Radiomics in COPD and Lung Cancer.
Refaee T; Wu G; Ibrahim A; Halilaj I; Leijenaar RTH; Rogers W; Gietema HA; Hendriks LEL; Lambin P; Woodruff HC
Respiration; 2020; 99(2):99-107. PubMed ID: 31991420
[TBL] [Abstract][Full Text] [Related]
33. Artificial intelligence-based prediction of clinical outcome in immunotherapy and targeted therapy of lung cancer.
Yin X; Liao H; Yun H; Lin N; Li S; Xiang Y; Ma X
Semin Cancer Biol; 2022 Nov; 86(Pt 2):146-159. PubMed ID: 35963564
[TBL] [Abstract][Full Text] [Related]
34. Next Generation of Lung Cancer Management.
Levy B
Oncology (Williston Park); 2019 Oct; 33(10):. PubMed ID: 31661148
[TBL] [Abstract][Full Text] [Related]
35. Combination of computed tomography imaging-based radiomics and clinicopathological characteristics for predicting the clinical benefits of immune checkpoint inhibitors in lung cancer.
Yang B; Zhou L; Zhong J; Lv T; Li A; Ma L; Zhong J; Yin S; Huang L; Zhou C; Li X; Ge YQ; Tao X; Zhang L; Son Y; Lu G
Respir Res; 2021 Jun; 22(1):189. PubMed ID: 34183009
[TBL] [Abstract][Full Text] [Related]
36. What does radiomics do in PD-L1 blockade therapy of NSCLC patients?
Cui R; Yang Z; Liu L
Thorac Cancer; 2022 Oct; 13(19):2669-2680. PubMed ID: 36039482
[TBL] [Abstract][Full Text] [Related]
37. Toward personalized treatment approaches for non-small-cell lung cancer.
Wang M; Herbst RS; Boshoff C
Nat Med; 2021 Aug; 27(8):1345-1356. PubMed ID: 34385702
[TBL] [Abstract][Full Text] [Related]
38. Management of KRAS-Mutant Non-Small Cell Lung Cancer in the Era of Precision Medicine.
Aredo JV; Padda SK
Curr Treat Options Oncol; 2018 Jun; 19(8):43. PubMed ID: 29951788
[TBL] [Abstract][Full Text] [Related]
39. Time to Rethink the Role of Clinical Pathways in the Era of Precision Medicine: A Lung Cancer Case Study.
Schleicher SM; Chaudhry B; Dickson NR; Aviki E; Arrowsmith E; Parikh RB; Yue AT; Connor N; Schwartzberg L; Lyss AJ
JCO Oncol Pract; 2021 Jul; 17(7):379-381. PubMed ID: 33872069
[No Abstract] [Full Text] [Related]
40. Integration of longitudinal deep-radiomics and clinical data improves the prediction of durable benefits to anti-PD-1/PD-L1 immunotherapy in advanced NSCLC patients.
Farina B; Guerra ADR; Bermejo-Peláez D; Miras CP; Peral AA; Madueño GG; Jaime JC; Vilalta-Lacarra A; Pérez JR; Muñoz-Barrutia A; Peces-Barba GR; Maceiras LS; Gil-Bazo I; Gómez MD; Ledesma-Carbayo MJ
J Transl Med; 2023 Mar; 21(1):174. PubMed ID: 36872371
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
